Inhibrx Biosciences (INBX) Net Income towards Common Stockholders (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$32.8 million in Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 31.4% year-over-year to -$32.8 million in Q4 2025; TTM through Dec 2025 was -$140.1 million, a 108.3% decrease from a year earlier, with the FY2025 full-year figure at -$140.1 million, down 108.3% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$32.8 million, up from -$35.3 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for INBX reached as high as $1.9 billion in Q2 2024 and fell as low as -$92.0 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged $123.3 million across 3 years, with a median of -$43.9 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders jumped 4048.85% in 2024 and slumped 101.54% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$92.0 million in 2023, then surged by 47.96% to -$47.9 million in 2024, then soared by 31.4% to -$32.8 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.